書誌事項
- タイトル別名
-
- Phase III clinical study of BAY 12-8039 (moxifloxacin) for respiratory tract infections
この論文をさがす
抄録
The efficacy and safety of BAY 12-8039 (moxifloxacin: MFLX), a novel new quinolone compound, were evaluated in patient with respiratory tract infections. Patients were treated for 7 days with MFLX 400 mg once daily.<BR>The clinical efficacy rate was 98.3%(57/58 cases) for acute upper respiratory tract infections (Group I), 100%(26/26) for atypical pneumonia (Group II-1) and 87.7%(57/65) for secondary infections (or acute exacerbation) in patient with chronic respiratory tract diseases (Group 11-2). The eradication rate was 100%(24/24) for Group I and 86.1%(31/36) for Group 11-2. The overall eradication rate was 91.7%(55/60). Good eradication rates were obtained in every diagnostic group.<BR>The incidence of adverse drug reactions were noted in 32.5%(65 cases) of all patients. Adverse drug reactions were most commonly observed in digestive organs in 20.0%(40 cases). The most common adverse drug reactions were abnormal liver function tests and diarrhea, and their incidence rate was 8.5%(17 cases) and 5.5%(11 cases), respectively.<BR>The above results suggested that 400mg of MFLX administered once daily should be clinically very useful in the treatment of respiratory tract infections.
収録刊行物
-
- 日本化学療法学会雑誌
-
日本化学療法学会雑誌 53 (Supplement3), 47-59, 2005
公益社団法人 日本化学療法学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390282681267312896
-
- NII論文ID
- 10017083546
- 130004298279
-
- NII書誌ID
- AN10472127
-
- ISSN
- 18845886
- 13407007
-
- 本文言語コード
- ja
-
- データソース種別
-
- JaLC
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可